Anzeige
Erschienen in:
29.09.2023 | First reports of adverse drug reactions
First reports of adverse drug reactions
Erschienen in: Drugs & Therapy Perspectives | Ausgabe 10/2023
Einloggen, um Zugang zu erhaltenExcerpt
Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by Reactions Weekly, the Adis drug safety newsletter. Reactions Weekly provides summaries of adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.
Table 1
First reports of adverse drug reactions
|
Drug: adverse reaction (all serious)
|
Reference
|
|---|---|
|
Risankizumab: bullous pemphigoid
|
Fukada N, et al. Bullous pemphigoid during the treatment of psoriasis vulgaris with risankizumab. J Dermatol. 2023;50(2):e72–3
|
|
Teriflunomide: lichenoid drug eruption
|
Agharbi F-Z, et al. Lichenoid drug eruption induced by teriflunomide. Ann Indian Acad Neurol. 2023;26(3):275–77
|
|
Catequentinib (anlotinib): central retinal vein occlusion
|
Chen Y, et al. Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review. Front Pharmacol. 2023;14:1188218
|
|
Ocrelizumab: viral pericarditis
|
Miele G, et al. Viral pericarditis following ocrelizumab in a multiple sclerosis patient. Neurol Sci. 2023;44(8):2947–9
|
|
Nivolumab: drug-induced discoid lupus erythematosus
|
Manjunath J, et al. Nivolumab-induced de novo discoid lupus erythematosus. Case Rep Dermatol. 2022;14(1):88–92
|
|
Bacillus Calmette Guerin (BCG): ulcerative colitis
|
Ferreira-Silva J, et al. A rare case of ulcerative colitis following Bacillus Calmette-Guerin therapy. Revista Espanola de Enfermedades Digestivas 2023;115(7):402–3
|